Source:http://linkedlifedata.com/resource/pubmed/id/18927318
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
2008-11-27
|
| pubmed:abstractText |
The anti-tumor response of human invariant NKT (NKT) cells is well established. A novel T cell subset, mucosal-associated invariant T (MAIT) cells, possesses similar regulatory properties to NKT cells in autoimmune models and disease. Here, we examined the clonality of four T cell subsets expressing invariant alphaTCR, including Valpha7.2-Jalpha33 of MAIT cells, in 19 kidney and brain tumors. The MAIT clonotype was identified and co-expressed with NKT clonotype in half of the tumors. In contrast, two other invariant T cell clonotypes (Valpha4 and Valpha19) were not present in tumors. Such tumors also expressed Vbeta2 and Vbeta13, the restricted TCRbeta chain of MAIT cells and the antigen-presenting molecule MR1. A high percentage of infiltrating T cells was CD8+ and expressed HLA-DR suggesting activation. Although the MAIT alphaTCR was identified in both peripheral CD56+ and CD56- subsets, infiltrating lymphocytes were CD56 negative. The clonal presence of MAIT cells in tumors correlated with the expression of pro-inflammatory cytokines but no IL-4, IL-5 and IL-10, suggesting that a pro-inflammatory subset of human MAIT cells may exist. Our data imply that a CD56- subset of MAIT cells may participate in tumor immune responses similarly to NKT cells.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1460-2377
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
20
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1517-25
|
| pubmed:meshHeading |
pubmed-meshheading:18927318-Antigens, CD56,
pubmed-meshheading:18927318-Brain Neoplasms,
pubmed-meshheading:18927318-Carcinoma, Renal Cell,
pubmed-meshheading:18927318-Cell Separation,
pubmed-meshheading:18927318-Cytokines,
pubmed-meshheading:18927318-Flow Cytometry,
pubmed-meshheading:18927318-Gene Expression,
pubmed-meshheading:18927318-Genes, T-Cell Receptor alpha,
pubmed-meshheading:18927318-Glioblastoma,
pubmed-meshheading:18927318-HLA-DR Antigens,
pubmed-meshheading:18927318-Humans,
pubmed-meshheading:18927318-Immunity, Mucosal,
pubmed-meshheading:18927318-Immunohistochemistry,
pubmed-meshheading:18927318-Kidney Neoplasms,
pubmed-meshheading:18927318-Lymphocyte Activation,
pubmed-meshheading:18927318-Lymphocytes, Tumor-Infiltrating,
pubmed-meshheading:18927318-Meningeal Neoplasms,
pubmed-meshheading:18927318-Meningioma,
pubmed-meshheading:18927318-Natural Killer T-Cells,
pubmed-meshheading:18927318-Polymorphism, Single-Stranded Conformational,
pubmed-meshheading:18927318-T-Lymphocyte Subsets
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
Invariant Valpha7.2-Jalpha33 TCR is expressed in human kidney and brain tumors indicating infiltration by mucosal-associated invariant T (MAIT) cells.
|
| pubmed:affiliation |
Department of Neurology.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|